A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Status:
Recruiting
Trial end date:
2024-05-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of treatment with long-acting injectable
(LAI) paliperidone (paliperidone palmitate 1-month [PP1M] and 3-month [PP3M] formulations) in
terms of clinical outcomes in participants with schizophrenia in Rwandan real-world
healthcare settings.